• The full-service CRO

    The CRO of choice
    by the leading Investigators

    and Sites

    Serving clients ranging
    from Big Pharma

    to Start-ups

    Combining Global Coverage with true Local Expertise

    In the United States, Europe, Russia and Asia, since 2001

    Continue to the website
    Download brochure

GCT partners with Chinese Pharma company to conduct Global Phase III trial in patients with NSCLC

GCT has been awarded the international multicenter phase III clinical trial of a tumor-starving (anti-angiogenic) therapy. The global enrollment target is 608 patients diagnosed with Non-Small Cell Lung Cancer. The first patient was randomized by GCT in the U.S. beginning of 2021.

March 29, 2021

COVID-19 Study in the U.S. Awarded to GCT

Global Clinical Trials has been selected to conduct a Phase I study in COVID-19 patients. The Investigational Medicinal Product is a nasal antiseptic formulation designed to ease the symptoms and reduce SAR COVID-19 viral load. It will be available over the counter for anyone in need.

March 11, 2021

GCT to collaborate with Greek Pharmaceutical Company in Russia

GCT was awarded a new regulatory project by a Greek Pharmaceutical company. It aims to develop a novel fixed-dose combination of the currently approved active substances doses into an immediate release film-coated tablet. The intended indication is “common cold with fever and nasal congestion”.

February 25, 2021

GCT organizes Investigators’ Meeting for medical device study in Romania

GCT started the new year with conducting an Investigators’ Meeting on behalf of the European Sponsor – NanoGun Technology (NGT). NGT is an innovative company certified by the French government in nanomaterial biotechnology. IMDENDRIM is an experimental in situ anticancer treatment of solid tumors nonresponsive to conventional therapy.

January 25, 2021

Study in Primary Mitochondrial Myopathy (PMM) Awarded

GCT has been selected to run a new project in patients diagnosed with PMM by its long-term Client. This Phase 2, multicenter, double-blind, placebo-controlled study will be managed by GCT team in Czech Republic and Hungary.

January 11, 2021

GCT Ukraine is moving to a larger facility

Global Clinical Trials first established its operations and a physical office in Ukraine in 2006. Among other projects, we are presently in the active start-up phase and opening 25 sites for a large global study in non-small lung cancer patients.

It is our pleasure to announce that we are moving to a new location to create an appropriate environment for our growing operations and headcount in the country.

January 7, 2021

Meet our clients

All trademarks, brand names and logotypes are intellectual property of their respective owners.

Upcoming meetings

CPhI Discover

CPhI Discover. Meet. Source. Discover.
2021, May 17—28
Online event

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.